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Introduction
Over the last decade, stimulation of glucagon-like
peptide-1 (GLP-1) receptor-mediated signalling has
been well validated as an approach for the treatment
of type 2 diabetes (T2DM). The GLP-1 receptor
agonists, GLP-1(7-36)-amide and GLP-1(7-37), here-
after collectively referred to as GLP-1, are produced
and secreted from enteroendocrine L-cells of the
intestinal epithelium. Key mechanisms responsible
for glucose lowering by GLP-1 receptor agonism are
stimulation of glucose-dependent insulin biosynthesis
and secretion, inhibition of glucagon release and
delayed gastric emptying.
Glucagon-like peptide-1 is rapidly hydrolysed
in vivo (t1 ⁄ 2  1–2 min) to produce a non-insulino-
tropic product, GLP-1(9-36) amide or GLP-1(9-37)
(1). Dipeptidyl peptidase-4 (DPP-4), a serine dipept-
idyl aminopeptidase that cleaves two N-terminal
amino acids from GLP-1 to generate a non-insulino-
tropic peptide with no agonist activity against the
GLP-1 receptor, is primarily responsible for this deg-
radation. Because of the rapid proteolysis of GLP-1
by DPP-4, the native peptide is not suitable for ther-
apeutic use. To overcome this problem, DPP-4-resis-
tant GLP-1 receptor agonists were developed as
injectable peptides for use in the treatment of
T2DM. Exenatide (exendin-4), a GLP-1 mimetic dis-
covered in lizard venom, was the ﬁrst of these pep-
tides approved for therapeutic use (2).
Pharmacological inhibition of DPP-4 is an alter-
nate approach to increase the circulating concentra-
tions of endogenous active GLP-1 (3). Multiple
DPP-4 inhibitors have been identiﬁed and shown to
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SUMMARY
Recent case reports of acute pancreatitis in patients with type 2 diabetes (T2DM)
treated with incretin-based therapies have triggered interest regarding the possibil-
ity of a mechanism-based association between pancreatitis and glucagon-like pep-
tide-1 mimetics or dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this
review was to describe the controlled preclinical and clinical trial data regarding
the incidence of pancreatitis with sitagliptin, the ﬁrst DPP-4 inhibitor approved for
use in patients with T2DM. Tissue samples from multiple animal species treated
with sitagliptin for up to 2 years at plasma exposures substantially in excess of
human exposure were evaluated to determine whether any potential gross or his-
tomorphological changes suggestive of pancreatitis occurred. Sections were pre-
pared by routine methods, stained with haematoxylin and eosin and examined
microscopically. A pooled analysis of 19 controlled clinical trials, comprising
10,246 patients with T2DM treated for up to 2 years, was performed using
patient-level data from each study for the evaluation of clinical and laboratory
adverse events. Adverse events were encoded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 12.0 system. Incidences of adverse events
were adjusted for patient exposure. Tissue samples from preclinical studies in mul-
tiple animal species did not reveal any evidence of treatment-related pancreatitis.
The pooled analysis of controlled clinical trials revealed similar incidence rates of
pancreatitis in patients treated with sitagliptin compared with those not treated
with sitagliptin (0.08 events per 100 patient-years vs. 0.10 events per 100 patient-
years, respectively). Preclinical and clinical trial data with sitagliptin to date do not
indicate an increased risk of pancreatitis in patients with T2DM treated with sitag-
liptin.
Review Criteria
An overview of the literature was performed to
describe the prevalence and aetiology of
pancreatitis. The effect of sitagliptin on pancreatic
histology was evaluated in different species
including mice, rats, dogs and monkeys. The
incidence of pancreatitis with sitagliptin was
analysed by pooling data from 19 controlled clinical
trials with sitagliptin.
Message for the Clinic
The incidence of pancreatitis is increased in
patients with type 2 diabetes (T2DM), and cases of
pancreatitis have been reported in patients using
most categories of antihyperglycemic medications.
Recent postmarketing reports of pancreatitis in
patients using incretin-based antihyperglycemic
medications [i.e. the glucagon-like peptide-1
receptor (GLP-1R) agonist, exenatide and the
dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin]
have focused attention on this issue. Review of
available preclinical and controlled clinical trial data
do not indicate an increased risk of pancreatitis in
patients treated with the DPP-4 inhibitor sitagliptin.
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984 doi: 10.1111/j.1742-1241.2010.02382.xstabilise endogenous active GLP-1 and improve gly-
caemic control in patients with T2DM. In addition
to cleavage of GLP-1, DPP-4 has been shown to
cleave multiple substrates in vitro, but few of these
substrates have been validated as physiological sub-
strates in humans. GLP-1 and another incretin,
glucose-dependent insulinotropic polypeptide (GIP),
are well-validated incretin substrates in humans, and
both are rapidly metabolised to inactive peptides by
the action of DPP-4. In mice, both GLP-1 and GIP
have been shown to mediate the acute glucose lower-
ing effects of DPP-4 inhibitor treatment in a glucose
challenge paradigm (4). In patients with T2DM,
however, because the insulinotropic effect of GIP
may be diminished in this disease, DPP-4 inhibitors
are believed to mediate glucose lowering primarily
via stabilisation of GLP-1 (5).
Interest in the relationship between antihypergly-
caemic agents (AHAs) and pancreatitis has recently
emerged, triggered originally by reports of acute pan-
creatitis in patients with T2DM treated with exena-
tide (6,7). Initially described in a case report in 2006,
subsequent postmarketing reports of acute pancreati-
tis in patients treated with exenatide as well as in
patients treated with the DPP-4 inhibitor sitagliptin
(8), the ﬁrst DPP-4 inhibitor approved for use in
patients with T2DM, have led to a focus on both the
preclinical and clinical experiences with exenatide,
other members of the GLP-1 agonist class, and the
DPP-4 inhibitor class. In this review, we discuss the
association of pancreatitis with T2DM, potential rela-
tionships between pancreatitis and medications other
than sitagliptin used to treat patients with T2DM,
and preclinical and clinical data on the incidence of
pancreatitis in patients treated with sitagliptin.
Aetiology and epidemiology
of pancreatitis in type 2 diabetes
mellitus
The aetiologies of pancreatitis have been well
described in numerous population studies (9). The
most common inciting factors are gallstones (35–
40%) and alcohol abuse (30%) (10). Other risk
factors for the development of acute pancreatitis
include anatomic abnormalities, hypertriglycerida-
emia, obesity, advancing age and use of drugs associ-
ated with pancreatitis. Patients with T2DM, who
have a higher incidence of several of these known
risk factors, have also been shown to have a higher
incidence of pancreatitis relative to the general popu-
lation. For example, in a multinational, placebo-
controlled clinical trial involving nearly 10,000
patients with T2DM, the incidence of pancreatitis in
the placebo group was 23 out of 4900 patients, or
0.47%, over 5 years (11), for an estimated incidence
rate of 0.094 per 100 patient-years. In comparison,
annual incidence rates of pancreatitis in the general
population have been reported to range from 0.004
to 0.045 per 100 patient-years (12). A recently
published study using retrospective claims data from
the Ingenix
  database, a large commercial US health
plan, assessed the incidence of acute pancreatitis in a
cohort of patients with T2DM; the reported inci-
dence rate of 0.422 cases per 100 patient-years was
greater than the rate of 0.149 cases per 100 patient-
years observed in a cohort of general medical
patients without diabetes [relative risk = 2.83 (95%
CI: 2.61, 3.06)] (13). The rate of pancreatitis
increased with age in the non-diabetes cohort, but
remained relatively constant with advancing age in
patients with T2DM. The reason(s) for the apparent
higher risk of pancreatitis in patients with diabetes
remains unclear, but may relate to the higher rates of
known risk factors for pancreatitis, such as obesity,
hypertriglyceridaemia, age and the greater use of
medications potentially associated with pancreatitis
in patients with T2DM.
Drug-induced pancreatitis
Drug-induced pancreatitis appears to be a relatively
uncommon cause of pancreatitis, although the actual
incidence is difﬁcult to determine (14). The use of
over 500 medications has been reported in patients
with pancreatitis in the literature as anecdotal case
reports, although the causal relationship of these
medications to cases of pancreatitis remains unclear.
This is due, in part, to incomplete information in the
case reports regarding dose, time course of onset of
pancreatitis in relation to initiation of the suspect
medication, other confounding potential aetiologies
and variable rechallenge experience. The interpreta-
tion of the aetiology of drug-induced pancreatitis in
patients with T2DM may frequently be confounded
by the concomitant use of medications that are com-
monly used in these patients and that have been asso-
ciated with reports of pancreatitis, including statins
and angiotensin-converting enzyme inhibitors (15).
Among published case reports of potential drug-
induced pancreatitis, there are few regarding AHAs.
Patients taking metformin have been reported to
develop pancreatitis, although all but one case report
involved an overdose or was in the setting of renal
failure (16–19). In a case–control study conducted in
Sweden between 1995 and 1998, the use of glyburide
among patients with T2DM was associated with
acute pancreatitis [adjusted odds ratio of 2.5 (95%
CI 1.1–5.9)] (20). The use of other members of the
sulphonylurea class in case reports of pancreatitis has
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described above, case reports of acute pancreatitis in
patients treated with exenatide have also been pub-
lished (6,23,24).
In contrast to the limited number of reports in the
literature, a relatively higher number of postmarket-
ing reports of pancreatitis associated with a broad
range of AHAs has appeared in various databases.
These postmarketing events are reported voluntarily
from a population of uncertain size; thus, it is gener-
ally not possible to establish reliably the frequency of
such events or to establish a causal relationship
between a medication and a speciﬁc adverse event.
The Adverse Event Reporting System (AERS), which
replaced the Spontaneous Reporting System (SRS) in
October 1997, is a computerised information data-
base designed to support the U.S. Food and Drug
Administration’s (FDA) postmarketing safety surveil-
lance program for all approved drug and therapeutic
biological products. However, as noted on the FDA
web site, ‘AERS data do have limitations. First, there
is no certainty that the reported event was actually
due to the product. FDA does not require that a cau-
sal relationship between a product and event be pro-
ven, and reports do not always contain enough detail
to properly evaluate an event. Further, FDA does not
receive all adverse event reports that occur with a
product. Many factors can inﬂuence whether or not
an event will be reported, such as the time a product
has been marketed and publicity about an event’
(25). In particular, changes in reporting rates over
time because of external factors (e.g. heightened
interest in a speciﬁc adverse event related to reports
of similar events with other medications or increased
reporting rates for newly introduced medications)
have been identiﬁed as signiﬁcant factors that con-
found comparisons between medications regarding
postmarketing reports of adverse events (26). Thus,
it is generally understood that ‘AERS cannot be used
to calculate the incidence of an adverse event in the
U.S. population’ (25).
Despite these limitations, the AERS database pro-
vides a method to aggregate submitted postmarketing
reports (27), which has resulted in recent updates to
the prescribing information regarding postmarketing
reports of pancreatitis for both exenatide and sitag-
liptin. In the context of the heightened interest
regarding the association of GLP-1 receptor agonists
and DPP-4 inhibitors with pancreatitis, a search of
the AERS and SRS databases for reports of pancreati-
tis observed with other classes of AHAs was con-
ducted by the authors, using data from 1968 through
the third quarter of 2008. This analysis revealed
reports of pancreatitis in patients using acarbose,
chlorpropamide, exenatide, glimepiride, glipizide,
insulin, metformin, miglitol, nateglinide, pioglitaz-
one, pramlintide, repaglinide and rosiglitazone. A
search of the same databases for commonly used
AHAs (not including insulin), using data from 1968
through the ﬁrst quarter of 2009, revealed cases of
severe pancreatitis (i.e. haemorrhagic or necrotising)
in which the following drugs were considered suspect
therapy: acarbose, metformin, glimepiride, repagli-
nide, pioglitazone and rosiglitazone, in addition to
exenatide and sitagliptin. Thus, pancreatitis in
patients receiving AHAs in the postmarketing envi-
ronment has been reported across a broad range of
mechanistic categories and across the entire range of
clinical severity. However, whether these reports are
truly reﬂective of a relationship between the medica-
tions and the development of pancreatitis, or simply
reﬂective of the increased rate of pancreatitis in the
population of patients with T2DM, remains undeter-
mined.
Pharmacoepidemiological studies can also be used
to assess the incidence of postmarketing adverse
events through the use of insurance or health system
databases that comprehensively capture diagnostic
and prescription information. In one such study,
Dore et al. reported that the rates of acute pancreati-
tis among exenatide- or sitagliptin-treated patients
were similar to those observed among metformin- or
glyburide-treated patients (28). Similarly, Herrera
et al. described similar rates of acute pancreatitis
among patients prescribed exenatide, sitagliptin or
other oral AHA therapies (29). While such data are
reassuring, retrospective pharmacoepidemiological
studies can be confounded by other factors (30). For
example, interpretation of such analyses can be lim-
ited by the preferential channelling of patients to
speciﬁc therapies, which can lead to a bias that can-
not easily be adjusted for when interpreting results
(31,32). Thus, controlled trials provide the most rig-
orous method for assessing the incidence of adverse
effects of treatments.
Preclinical studies of sitagliptin
Extensive preclinical toxicity studies were performed
as part of the sitagliptin development programme
that informs on the occurrence of pancreatitis in a
range of animal species: in rats, separate 2-week,
3-month, 6-month and 2-year studies comprising
approximately 600 rats exposed to sitagliptin; in
mice, separate 3-month and 2-year studies compris-
ing approximately 550 mice exposed to sitagliptin; in
dogs, 2-week, 3-month, 6-month and 1-year studies
comprising 96 dogs exposed to sitagliptin as well as
a 3-month study comprising 45 dogs exposed to the
combination of sitagliptin and metformin; and in
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gus monkeys exposed to sitagliptin (33).
In these studies in non-diabetic animals, sections
from the pancreas were reviewed for potential pan-
creatic toxicity. In all species studied, the pancreas
was carefully evaluated to determine whether any
potential gross or histomorphological changes associ-
ated with administration of sitagliptin occurred.
Sections were prepared by routine methods, stained
with haematoxylin and eosin, and examined micro-
scopically. Oral administration of sitagliptin for
3 months in monkeys, up to 12 months in dogs and
up to 2 years in rats and mice was not associated
with gross or histomorphological changes in the pan-
creas. There was no evidence of drug treatment-
related acute pancreatitis in any species studied.
These preclinical toxicity studies were performed
with doses that provided plasma exposures in excess
of anticipated human exposures (based on the recom-
mended dose of sitagliptin 100 mg⁄day), as measured
by the 24-h area under the plasma concentration time
curve (AUC0–24). In the above studies, the highest
dose tested in a 3-month study in rats was
2000 mg⁄kg⁄day, providing approximately a 271-fold
margin over human exposure. In a 6-month study in
rats, the highest dose studied was 180 mg⁄kg⁄day,
providing approximately a 23-fold margin over
human exposure. In the 2-year rat and mouse studies,
the highest dose studied was 500 mg⁄kg⁄day, provid-
ing approximately a 56- and 68-fold margin, respec-
tively, over human exposure. In dogs, the highest dose
studied was 50 mg⁄kg⁄day, providing approximately
a 28-fold margin over human exposure. In monkeys,
the highest dose studied was 100 mg⁄kg⁄day, provid-
ing approximately a 28-fold margin over human
exposure. Thus, at exposures well in excess of the
expected human exposure, these preclinical studies
did not reveal any evidence that administration of
high doses of sitagliptin results in changes in the pan-
creas of non-diabetic rats, mice, dogs or monkeys.
A recent publication by Matveyenko et al. reported
studies in which sitagliptin and metformin were
administered orally to transgenic rats overexpressing
human islet amyloid polypeptide (HIP) in the pan-
creas, a potential model of human T2DM (34). In
one of these studies, 2-month old wild-type and HIP
rats were fed a high-fat diet (HFD) and assigned to
one of ﬁve groups (n = 7–9); wild-type (no drug),
HIP rats (no drug), HIP rats administered sitagliptin
(200 mg⁄kg⁄day), HIP rats administered metformin
(200 mg⁄kg⁄day) and HIP rats administered sitaglip-
tin (200 mg⁄kg⁄day) + metformin (200 mg⁄kg⁄day).
Exposure levels in the HIP rats following a dose of
200 mg⁄kg⁄day of sitagliptin were not reported in
this study but, based on previous data, this dose is
likely to have produced exposures approximately 20-
fold above exposures likely to occur in humans
administered the recommended dose of sitagliptin
100 mg⁄day. Sitagliptin and metformin were admin-
istered orally for 12 weeks. In this study, upon histo-
morphological evaluation of the pancreas from these
transgenic animals, it was noted that one of the 16
animals treated with sitagliptin, with or without met-
formin, had an area of pancreatitis. This area showed
marked necrotising pancreatitis characterised by
haemorrhagic necrosis, ﬁbrosis, inﬂammatory cell
inﬁltration and areas of ductal metaplasia. The
authors stated that there were no observed effects in
any HIP rats not treated with sitagliptin, and that
pancreatitis was not observed in any of the other 89
HIP rats evaluated previously. However, the interpre-
tation of this isolated ﬁnding is complicated by the
limited amount of appropriate control data. The his-
torical data referenced in the paper appears to
include only approximately 13 HIP rats that were
placed on HFD to induce insulin resistance and
hyperglycaemia. Thus, in the historical ‘control’
database, the limited number of animals fed a HFD
may have inﬂuenced the incidence of pancreatitis.
In contrast to the above ﬁndings of Matveyenko
et al. (34), using the high-fat⁄streptozotocin murine
model for T2DM in studies conducted at Merck
Research Laboratories (35), no pancreatic histopatho-
logical effects were observed with sitagliptin treatment
(33). To generate this model, 4-week-old male ICR
mice were placed on a HFD in which 60% of energy
intake is from fat. After 3 weeks of HFD, the mice are
injected once with low-dose streptozotocin (90–
100 mg⁄kg i.p.) to induce partial insulin deﬁciency.
Three weeks after streptozotocin injection, the major-
ity of HFD⁄streptozotocin-treated mice display hyper-
glycaemia, insulin resistance and glucose intolerance.
The original purpose of this study was to explore the
effects of sitagliptin on beta cell mass and function,
and the primary results of the study have been recently
published (36). In this study, ﬁfty 10-week old mice
were treated with sitagliptin at doses of up to
840 mg⁄kg⁄day for up to 10 weeks, resulting in
estimated exposures (based on exposure data in CD-1
mice from a 14-week dose-range-ﬁnding study
conducted to support the development of sitagliptin)
as high as approximately 120-fold relative to the
exposure in humans administered the recommended
dose of 100 mg⁄day. Background changes of very
slight focal chronic inﬂammation were seen in the
pancreas in both control (N = 41) and streptozotocin-
treated (N = 41) animals at similar incidences, with
no difference noted in sitagliptin-treated animals (33).
Of additional note is the study by Koehler et al., in
which the effect of sitagliptin on the expression of
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in mice was compared with metformin and the GLP-1
receptor agonists exenatide and liraglutide (37).
In contrast to the GLP-1 receptor agonists,
neither sitagliptin nor metformin signiﬁcantly altered
pancreatic gene expression proﬁles. The same labora-
tory reported that in C57BL⁄6 mice (N = 6) treated
with sitagliptin at doses as high as 370 mg⁄kg⁄day,
no histological evidence of pancreatitis was noted (D.
Drucker, personal communication, University of
Toronto, Toronto, ON, Canada). Another recent
report described an increase in pancreatic acinar
inﬂammation in Sprague–Dawley rats after chronic
administration of exenatide 10 lg⁄kg (38), although
the potential mechanism(s) responsible for this
ﬁnding in this rat model remains speculative.
Thus, with the exception of a report of the histo-
logical ﬁndings in a single animal from a study of a
genetically-altered rat model of diabetes, a broad
range of preclinical studies in both non-diabetic and
diabetic animals at exposures exceeding human expo-
sure did not demonstrate a relationship between use
of sitagliptin and the development of pancreatitis.
Clinical experience with sitagliptin
A previously published, pooled analysis of data from
12 double-blind, randomised clinical studies of up to
2 years in duration in patients with T2DM, compris-
ing 6139 patients treated with either sitagliptin or a
comparator agent (placebo or other AHA), was
conducted to assess for differences in the incidence
of adverse events between patients treated with
sitagliptin and patients not exposed to sitagliptin
(39). This pooled population included patients
treated with the usual clinical dose of sitagliptin
100 mg⁄day (administered either as 100 mg q.d. or
50 mg b.i.d.) or concurrent control for between 12
and 106 weeks in clinical studies that were complete
as of November 2007. Patients in the sitagliptin
group (N = 3415) received sitagliptin when used as
monotherapy, initial combination therapy with
metformin, or add-on combination therapy with
other AHAs including metformin, pioglitazone, a
sulphonylurea (with and without metformin), or
metformin + rosiglitazone. Patients in the control
(non-exposed) group (N = 2724) received placebo,
pioglitazone, metformin, a sulphonylurea (with and
without metformin), or metformin + rosiglitazone.
From each contributing study, the pooling was
conducted by including portions of studies with
controlled, parallel treatment groups. In this pooled
analysis, no difference in the incidence of pancreatitis
between patients treated with sitagliptin and patients
not exposed to sitagliptin was observed (39).
To examine more comprehensively the safety and
tolerability of sitagliptin, an updated pooled analysis
of data from 19 double-blind, randomised clinical
studies (including 7 additional studies relative to the
prior pooled analysis) of up to 2 years in duration in
patients with T2DM that were complete as of July
2009, and comprising 10,246 patients treated with
either sitagliptin or a comparator agent (placebo or
other AHA), was recently completed. Patients in the
sitagliptin group (N = 5429) received sitagliptin (as
either 100 mg q.d. or 50 mg b.i.d.) when used as
monotherapy, initial combination therapy with either
metformin or pioglitazone, or add-on combination
therapy with other AHAs including metformin,
pioglitazone, a sulphonylurea (with and without
metformin), insulin (with and without metformin),
or metformin + rosiglitazone. Patients in the
non-exposed group (N = 4817) received placebo,
pioglitazone, metformin, a sulphonylurea (with and
without metformin), insulin (with and without
metformin), or metformin + rosiglitazone. As in the
prior pooled analysis, from each contributing study,
the pooling was conducted by including portions of
studies with controlled, parallel treatment groups.
This safety analysis used patient-level data from
each study for the evaluation of clinical and labora-
tory adverse events. Adverse events were encoded
using the MedDRA (Medical Dictionary for Regula-
tory Activities; version 12.0) system, a validated ter-
minology database developed by the International
Conference on Harmonisation. The speciﬁc MedDRA
preferred terms used in this analysis were pancreati-
tis, acute pancreatitis and chronic pancreatitis. To
account for the different exposures for the sitagliptin
group compared with the non-exposed group, an
exposure-adjusted analysis of incidence was con-
ducted. For patients who had one or more events,
person-time was computed beginning with the date
of randomisation and ending with the date of the
ﬁrst event. For patients who did not have an event,
person-time was computed beginning with the date
of randomisation and ending 14 days after the last
dose of study medication. Adverse events were
expressed as exposure-adjusted incidence rates (i.e.
number of patients with an event divided by patient-
years of exposure). Differences in incidence rates
between treatment groups were computed for all
end-points, and the corresponding 95% conﬁdence
intervals (CIs) were calculated using the method of
Miettinen and Nurminen (40), stratiﬁed by study. In
most studies included in this analysis, glycaemic
rescue therapy was to be implemented based upon
protocol-speciﬁed hyperglycaemic criteria. Glycaemic
rescue medications included metformin, pioglitazone,
a sulphonylurea, or increased doses of insulin (in the
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safety population focused on the results that
included data obtained both before and after a
patient initiated rescue therapy.
As presented in Table 1, the incidence rate for the
combined adverse events of pancreatitis and pancrea-
titis acute was similar for both groups (0.08 and 0.10
per 100 patient-years), with a between-group differ-
ence (95% CI) of )0.02 ()0.20, 0.14). For the spe-
ciﬁc events of ‘pancreatitis acute’ and ‘pancreatitis’,
the 95% CI for the between-group difference in the
event rates also included zero. For the adverse event
of chronic pancreatitis, the event rates per 100
patient-years were 0.04 and 0.03 for the sitagliptin
group and the non-sitagliptin-exposed group, respec-
tively, with a between-group difference (95% CI) of
0.02 ()0.11, 0.13). In these clinical trials, there were
no cases of haemorrhagic or necrotising pancreatitis,
and no fatalities associated with pancreatitis were
reported. Among the four patients in the sitagliptin
group who had an adverse event of pancreatitis or
pancreatitis acute, one had a prior medical history of
recurrent pancreatitis, two had pancreatitis associated
with gallstones and one had severe hypertriglycerida-
emia. Among the four patients in the non-exposed
group who had an adverse event of pancreatitis or
pancreatitis acute, two had a prior medical history of
chronic pancreatitis. Thus, this recent pooled analysis
of 19 controlled clinical studies does not suggest an
increased risk of pancreatitis in patients treated with
sitagliptin.
Conclusion
Assessment of the safety of investigational and mar-
keted drugs is an ongoing process that incorporates
a variety of distinct, yet complementary, approaches.
These approaches include, among others, preclinical
studies in multiple species, typically involving drug
exposures that greatly exceed the anticipated expo-
sure in patients; controlled Phase I clinical studies
in healthy subjects, also typically involving drug
exposures that exceed the anticipated exposure in
patients; controlled Phase II and Phase III clinical
studies in the targeted patient population at thera-
peutic drug exposures; and postapproval analyses of
clinical trial data, spontaneous postmarketing reports
of adverse events and pharmacoepidemiological
studies of large databases. As described in the pres-
ent report, the preclinical and clinical trial data
developed with sitagliptin to date do not indicate an
increased risk of pancreatitis in patients with T2DM
treated with sitagliptin. Nevertheless, as postmarket-
ing events of pancreatitis have been reported for
patients with diabetes while being treated with vari-
ous AHAs, including sitagliptin, continued surveil-
lance of the postmarketing experience and
assessment of adverse events in patients participating
in controlled clinical trials with sitagliptin are ongo-
ing. Additional preclinical and clinical studies that
are directed towards a better understanding of the
potential relationship between speciﬁc medications,
diabetes itself, and the incidence and severity of
pancreatitis may lead to further knowledge in this
area.
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Table 1 Person-time adjusted analysis of pancreatitis and pancreatitis acute adverse events including data after
glycaemic rescue: sitagliptin 100 mg vs. non-exposed
Adverse event end-point Treatment
n/Patient-years of exposure
(100 patient-years event rate)*
Difference vs. non-exposed
(95% CI)
Pancreatitis⁄pancreatitis acute Sitagliptin 100 mg 4⁄4708 (0.08) )0.02 ()0.20, 0.14)
Non-exposed 4⁄3942 (0.10)
Pancreatitis Sitagliptin 100 mg 3⁄4708 (0.06) 0.06 ()0.04, 0.19)
Non-exposed 0⁄3943 (0.00)
Pancreatitis acute Sitagliptin 100 mg 1⁄4709 (0.02) )0.08 ()0.25, 0.03)
Non-exposed 4⁄3942 (0.10)
n = Number of patients with ‡ 1 occurrence of the end-point.
*Patient-years of exposure were computed as the total time in the treatment period + 14 days for patients who did not have an
event, and as the total time up to the time of the ﬁrst event for patients who had an event.
95% CI computed using the Miettinen & Nurminen method stratiﬁed by study.
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